Plant Name: Hedychium spicatum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.730E-14 | 1.256E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.739E-13 | 7.573E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.028E-12 | 3.731E-09 | CA1, CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.151E-12 | 6.692E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.707E-12 | 9.895E-09 | CA1, CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.252E-11 | 2.530E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.394E-11 | 2.530E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.302E-11 | 3.581E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.431E-11 | 4.669E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.114E-10 | 3.583E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.794E-09 | 2.430E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 7.218E-08 | 4.030E-05 | AKR1B1, CYP19A1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.076E-07 | 1.027E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.659E-06 | 7.225E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 2.431E-06 | 9.987E-04 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.054E-06 | 1.146E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.054E-06 | 1.146E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 4.179E-06 | 1.517E-03 | AKR1B1, CYP19A1, CYP1A2, XDH |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 5.283E-06 | 1.826E-03 | AKR1B1, CA2, CYP1A1, CYP1A2, CYP1B1, HIF1A |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.104E-06 | 2.014E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.017E-05 | 3.255E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0016614; oxidoreductase activity, acting on CH-OH group of donors | 1.044E-05 | 3.293E-03 | AKR1B1, CBR1, HSD17B10, XDH |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.524E-05 | 4.546E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 1.524E-05 | 4.546E-03 | CA1, CA2 |
| BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 2.080E-05 | 6.121E-03 | AKR1B1, CYP19A1, CYP1A2, XDH |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.132E-05 | 6.191E-03 | CYP1A2, CYP3A4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.458E-05 | 6.861E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.841E-05 | 7.831E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 3.288E-05 | 8.949E-03 | AKR1B1, CYP19A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.676E-15 | 2.914E-11 | CA1, CA12, CA2, CA4, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.365E-15 | 2.629E-13 | CA12; CA1; CA2; CA4; CA7; CA9 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.113E-12 | 2.727E-11 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.135E-11 | 1.165E-09 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.578E-09 | 3.159E-08 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 8.374E-08 | 6.839E-07 | CYP2C9; CBR1; CYP1A2; CYP1A1; AKR1B1; CYP2C19; CYP3A4; CYP19A1; HSD17B10; XDH |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.699E-08 | 1.665E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.733E-07 | 3.313E-06 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.028E-07 | 3.692E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 8.252E-06 | 4.493E-05 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.627E-05 | 7.246E-05 | CYP1A1; CYP1B1; CYP19A1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.115E-05 | 1.272E-04 | CYP2C9; CBR1; CYP2C19 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.680E-05 | 1.764E-04 | CA2; CYP3A4; ABCG2 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 9.577E-04 | 3.128E-03 | CYP3A4; XDH |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.529E-03 | 1.693E-02 | CYP2C9; CYP2C19 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.374E-04 | 8.307E-04 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.483E-06 | 4.647E-05 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; HIF1A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; HIF1A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |